Key result
Immunometabolic dysregulation in women is linked to ~225% higher mortality risk versus low dysregulation.
Why the study?
Although high allostatic load is known to increase mortality risk, this study sought to use latent profile analysis and survival techniques to assess how allostatic load status relates to time to death.
Does immunometabolic dysregulation or parasympathetic reactivity increase the risk of mortality compared to low dysregulation in adults?
Cohort (n=815)
Does immunometabolic dysregulation or parasympathetic reactivity increase the risk of mortality compared to low dysregulation in adults?
Effect estimate: HR 3.25 (95% CI 1.47 to 7.07)
Immunometabolic dysregulation is associated with a significantly increased risk of mortality in women, highlighting sex-specific risks of allostatic load.
Sex-specific mortality association merits targeted investigation; leaves open causal role and intervention targets for immunometabolic dysregulation.
BACKGROUND: There is a well-established relationship between high allostatic load (AL) and increased risk of mortality. This study expands on the literature by combined latent profile analysis (LPA) with survival data analysis techniques to assess the degree to which AL status is associated with time to death. METHODS: LPA was employed to identify underlying classes of biological dysregulation among a sample of 815 participants from the Midlife in the US study. Sex-stratified Cox proportional hazards regression models were used to estimate the association between class of biological dysregulation and time to death while controlling for sociodemographic covariates. RESULTS: The LPA resulted in three classes: low dysregulation, immunometabolic dysregulation and parasympathetic reactivity. Women in the immunometabolic dysregulation group had more than three times the risk of death as compared with women in the low dysregulation group (HR=3.25, 95% CI: 1.47 to 7.07), but that there was not a statistically significant difference between the parasympathetic reactivity group and the low dysregulation group (HR=1.80, 95% CI: 0.62 to 5.23). For men, the risk of death for those in the immunometabolic dysregulation (HR=1.79, 95% CI: 0.88 to 3.65) and parasympathetic reactivity (HR=0.90, 95% CI: 0.34 to 3.65) groups did not differ from the low dysregulation group. CONCLUSION: The findings are consistent with the previous research that demonstrates increased AL as a risk factor for mortality. Specifically, in women, that increased risk may be associated with immunometabolic dysregulation and not simply a generalised measure of cumulative risk as is typically employed in AL research.
No takes yet. Share an insight, caveat, or question.
Carbone et al. (2023) conducted a cohort in Allostatic load (n=815). Immunometabolic dysregulation vs. Low dysregulation was evaluated on Time to death (HR 3.25, 95% CI 1.47 to 7.07). Women with immunometabolic dysregulation had a significantly higher risk of death compared to those with low dysregulation (HR 3.25; 95% CI 1.47 to 7.07).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: